Does use of β-blockers reduce all-cause mortality or heart failure hospitalization in patients with HFPEF?
Observational data suggests beta-blockers may lower all-cause mortality in HFpEF, but large randomized clinical trials are needed to confirm this finding.
In patients with HFPEF, use of β-blockers was associated with lower all-cause mortality but not with combined all-cause mortality or heart failure hospitalization. β-Blockers in HFPEF should be examined in a large randomized clinical trial.
Lund et al. (2014) studied this question.